# Boehringer Ingelheim completes $228M biologics facility expansion in Fremont

Boehringer Ingelheim completed the expansion of its biopharmaceutical manufacturing facility in Fremont, California, with a $228 million investment over two years, creating 300 new jobs and increasing worldwide bioreactor capacity to 290,000 liters.

- Type: Expansion
- Announced: 2018-11-01
- Where: Fremont, California, United States
- Value: $228.0M
- Jobs: 300
- Starts operating: 1 Nov 2018
- Status: completed
- Capacity: 290,000 liters bioreactor capacity
- Products: biopharmaceutical medicines
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Boehringer Ingelheim](https://endata.com/companies/25171.md)

## Sources

- [process-worldwide.com](https://www.process-worldwide.com/boehringer-ingelheim-completes-expansion-of-biologics-production-a-772069/), 2018-11-01: "The company announced that it was now well-positioned to manufacture future biopharmaceutical medicines, both from its own research pipeline and as a contract manufacturer for other pharmaceutical and biopharmaceutical companies."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.